Ixico secures three new contracts, appoints chief business officer
AI data analytics company Ixico said on Monday that it had secured three new contracts and appointed a chief business officer.
FTSE AIM All-Share
755.55
11:45 26/04/24
Ixico
8.57p
10:50 26/04/24
Pharmaceuticals & Biotechnology
22,695.88
11:44 26/04/24
The AIM-listed group has secured a start-up agreement with a new client for a new multi-study programme in progressive supranuclear palsy (PSP), with an initial value of around £0.4m, over 12 months.
It has also landed a £0.35m, three-year, expansion of an existing study to add a significant patient cohort in China and a two-year, £0.45m contract to support a Phase IV study for a US biotech client, exploring a new application for a marketed drug for mental health.
Ixico also said it had appointed Lammert Albers as its chief business officer with immediate effect.
Chief executive officer Giulio Cerroni said: "Following an exceptionally strong close in FY19, we are pleased to keep up this momentum with new contracts and new commercial leadership talent coming on board. This demonstrates the adaptability of Ixico's core technology and ability to unlock insights on a broad range of neurological disorders and across the full spectrum of clinical development."
Albers said Lammert brings "deep knowledge of the global CNS clinical trials market and a strong track record of delivering revenue growth".
"His experience will further support our strategy of growth through international expansion," Cerroni said.
At 1315 GMT, the shares were up 11% at 77.00p.